Predicting Drug-Induced Cholestasis with the Help of Hepatic Transporters—An in Silico Modeling Approach
暂无分享,去创建一个
[1] Yanli Wang,et al. PubChem BioAssay: 2014 update , 2013, Nucleic Acids Res..
[2] M. Roma,et al. Hepatocellular transport in acquired cholestasis: new insights into functional, regulatory and therapeutic aspects. , 2008, Clinical science.
[3] K. Brouwer,et al. Risk Factors for Development of Cholestatic Drug-Induced Liver Injury: Inhibition of Hepatic Basolateral Bile Acid Transporters Multidrug Resistance-Associated Proteins 3 and 4 , 2014, Drug Metabolism and Disposition.
[4] E. Russo,et al. Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two “challenging” case reports , 2013, Journal of pharmacology & pharmacotherapeutics.
[5] Sander B Nabuurs,et al. In silico identification of potential cholestasis-inducing agents via modeling of Na(+)-dependent taurocholate cotransporting polypeptide substrate specificity. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[6] K. Faber,et al. Drug transport proteins in the liver. , 2003, Advanced drug delivery reviews.
[7] T. Horie,et al. Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes. , 2011, Biochemical and biophysical research communications.
[8] Tom Fawcett,et al. An introduction to ROC analysis , 2006, Pattern Recognit. Lett..
[9] Stefan Kramer,et al. A Large‐Scale Empirical Evaluation of Cross‐Validation and External Test Set Validation in (Q)SAR , 2013, Molecular informatics.
[10] Dragos Horvath,et al. Prediction of drug induced liver injury using molecular and biological descriptors. , 2015, Combinatorial chemistry & high throughput screening.
[11] J. Guo,et al. Risk of Hepatotoxicity Associated with the Use of Telithromycin: A Signal Detection Using Data Mining Algorithms , 2008, The Annals of pharmacotherapy.
[12] George Kollias,et al. Ligand-based virtual screening procedure for the prediction and the identification of novel β-amyloid aggregation inhibitors using Kohonen maps and Counterpropagation Artificial Neural Networks. , 2011, European journal of medicinal chemistry.
[13] N. Kaplowitz,et al. Mechanisms of drug-induced liver injury. , 2013, Clinics in liver disease.
[14] P. Bernardi,et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.
[15] K. Kuchler,et al. Flagging Drugs That Inhibit the Bile Salt Export Pump. , 2016, Molecular pharmaceutics.
[16] N. Kawada,et al. [Drug-induced cholestasis]. , 1995, Ryoikibetsu shokogun shirizu.
[17] Emese Kis,et al. BSEP inhibition: in vitro screens to assess cholestatic potential of drugs. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.
[18] Yoav Freund,et al. Experiments with a New Boosting Algorithm , 1996, ICML.
[19] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[20] Leo Breiman,et al. Bagging Predictors , 1996, Machine Learning.
[21] A. Mottino,et al. Dynamic localization of hepatocellular transporters in health and disease. , 2008, World journal of gastroenterology.
[22] Weida Tong,et al. FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.
[23] Alexander Amberg,et al. Computational Models for Human and Animal Hepatotoxicity with a Global Application Scope. , 2016, Chemical research in toxicology.
[24] B. Hagenbuch,et al. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies , 2012, British journal of pharmacology.
[25] M. Trauner,et al. Bile acid transporters and regulatory nuclear receptors in the liver and beyond , 2013, Journal of hepatology.
[26] A. Tropsha,et al. An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. , 2013, Journal of pharmaceutical sciences.
[27] Louis-David Cantin,et al. Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs: Opportunities Provided by Physicochemical Property Modulation, In Silico Modeling, and Structural Modification , 2012, Drug Metabolism and Disposition.
[28] Yuichi Sugiyama,et al. Inhibition of Bile Acid Transport across Na+/Taurocholate Cotransporting Polypeptide (SLC10A1) and Bile Salt Export Pump (ABCB 11)-Coexpressing LLC-PK1 Cells by Cholestasis-Inducing Drugs , 2006, Drug Metabolism and Disposition.
[29] Sean Ekins,et al. Progress in computational toxicology. , 2014, Journal of pharmacological and toxicological methods.
[30] Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. , 1990, International journal of clinical pharmacology, therapy, and toxicology.
[31] Richard J. Thompson,et al. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. , 2002, Gastroenterology.
[32] George Kollias,et al. In Silico Exploration for Identifying Structure–Activity Relationship of MEK Inhibition and Oral Bioavailability for Isothiazole Derivatives , 2010, Chemical biology & drug design.
[33] Ivan Rusyn,et al. Modeling liver-related adverse effects of drugs using knearest neighbor quantitative structure-activity relationship method. , 2010, Chemical research in toxicology.
[34] O. Fardel,et al. The drug efflux pump MRP2: Regulation of expression in physiopathological situations and by endogenous and exogenous compounds , 2004, Cell Biology and Toxicology.
[35] Stefan Brenner,et al. Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) Using a Consensus Vote of Six Classification Models , 2015, Molecular pharmaceutics.
[36] Peter J. Meier,et al. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties , 2004, Pflügers Archiv.
[37] Hugh A. Barton,et al. Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury , 2014, Front. Pharmacol..
[38] J. G. Kenna,et al. In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans , 2012, Drug Metabolism and Disposition.
[39] Xiao Fu,et al. A Liver-Centric Multiscale Modeling Framework for Xenobiotics , 2016, PloS one.
[40] Gerd A. Kullak-Ublick,et al. Drug-Induced Cholestatic Liver Disease , 2013 .
[41] C. Bénichou. Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.
[42] W. Alrefai,et al. Bile Acid Transporters: Structure, Function, Regulation and Pathophysiological Implications , 2007, Pharmaceutical Research.
[43] Alexander Golbraikh,et al. A Novel Automated Lazy Learning QSAR (ALL-QSAR) Approach: Method Development, Applications, and Virtual Screening of Chemical Databases Using Validated ALL-QSAR Models , 2006, J. Chem. Inf. Model..
[44] M. Vihinen. How to evaluate performance of prediction methods? Measures and their interpretation in variation effect analysis , 2012, BMC Genomics.
[45] K. Kuchler,et al. Subtle Structural Differences Trigger Inhibitory Activity of Propafenone Analogues at the Two Polyspecific ABC Transporters: P‐Glycoprotein (P‐gp) and Breast Cancer Resistance Protein (BCRP) , 2016, ChemMedChem.
[46] P. Watkins,et al. Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid–Mediated DILI , 2014, CPT: pharmacometrics & systems pharmacology.
[47] CHUN WEI YAP,et al. PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..
[48] Weida Tong,et al. Toward predictive models for drug-induced liver injury in humans: are we there yet? , 2014, Biomarkers in medicine.
[49] Arie Regev,et al. Drug-Induced Liver Injury and Drug Development: Industry Perspective , 2014, Seminars in Liver Disease.
[50] J. Friedman. Special Invited Paper-Additive logistic regression: A statistical view of boosting , 2000 .
[51] F. Russel,et al. In silico identification and in vitro validation of potential cholestatic compounds through 3D ligand-based pharmacophore modeling of BSEP inhibitors. , 2014, Chemical research in toxicology.
[52] Ferran Sanz,et al. eTOXlab, an open source modeling framework for implementing predictive models in production environments , 2015, Journal of Cheminformatics.
[53] S. Erlinger. NTCP deficiency: a new inherited disease of bile acid transport. , 2015, Clinics and research in hepatology and gastroenterology.
[54] Pedro M. Domingos. MetaCost: a general method for making classifiers cost-sensitive , 1999, KDD '99.
[55] Paul B Watkins,et al. Drug‐induced liver injury: Summary of a single topic clinical research conference , 2006, Hepatology.
[56] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[57] Manfred Hauben,et al. Early Postmarketing Drug Safety Surveillance: Data Mining Points to Consider , 2004, The Annals of pharmacotherapy.
[58] Peer Bork,et al. The SIDER database of drugs and side effects , 2015, Nucleic Acids Res..
[59] P. Meier,et al. Hepatobiliary transporters and drug‐induced cholestasis , 2006, Hepatology.
[60] Maarten L J Coonen,et al. Classification of hepatotoxicants using HepG2 cells: A proof of principle study. , 2014, Chemical research in toxicology.
[61] F. Ballet,et al. Hepatotoxicity in drug development: detection, significance and solutions. , 1997, Journal of hepatology.
[62] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[63] Ian H. Witten,et al. The WEKA data mining software: an update , 2009, SKDD.
[64] Naomi L Kruhlak,et al. Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data. , 2014, Toxicology.
[65] Gerhard Klebe,et al. Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures , 1994, J. Chem. Inf. Comput. Sci..
[66] J. VandeBerg,et al. Hepatobiliary transport in health and disease , 2012, Clinical lipidology.